JP7501960B2 - ビスホスホネート・キノロン複合体及びそれらの用途 - Google Patents

ビスホスホネート・キノロン複合体及びそれらの用途 Download PDF

Info

Publication number
JP7501960B2
JP7501960B2 JP2021500846A JP2021500846A JP7501960B2 JP 7501960 B2 JP7501960 B2 JP 7501960B2 JP 2021500846 A JP2021500846 A JP 2021500846A JP 2021500846 A JP2021500846 A JP 2021500846A JP 7501960 B2 JP7501960 B2 JP 7501960B2
Authority
JP
Japan
Prior art keywords
group
substituted
bone
linker
quinolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532087A5 (https=
JP2021532087A (ja
Inventor
エイチ． エベティーノ、フランク
スン、シューティン
ティー． シェリアン、フィリップ
Original Assignee
バイオビンク エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオビンク エルエルシー filed Critical バイオビンク エルエルシー
Publication of JP2021532087A publication Critical patent/JP2021532087A/ja
Publication of JP2021532087A5 publication Critical patent/JP2021532087A5/ja
Application granted granted Critical
Publication of JP7501960B2 publication Critical patent/JP7501960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2021500846A 2018-07-09 2019-07-09 ビスホスホネート・キノロン複合体及びそれらの用途 Active JP7501960B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695583P 2018-07-09 2018-07-09
US62/695,583 2018-07-09
PCT/US2019/041063 WO2020014269A1 (en) 2018-07-09 2019-07-09 Bisphosphonate quinolone conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2021532087A JP2021532087A (ja) 2021-11-25
JP2021532087A5 JP2021532087A5 (https=) 2022-06-10
JP7501960B2 true JP7501960B2 (ja) 2024-06-18

Family

ID=69142455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500846A Active JP7501960B2 (ja) 2018-07-09 2019-07-09 ビスホスホネート・キノロン複合体及びそれらの用途

Country Status (5)

Country Link
EP (1) EP3820565A4 (https=)
JP (1) JP7501960B2 (https=)
CN (1) CN112672787A (https=)
CA (1) CA3105829A1 (https=)
WO (1) WO2020014269A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285489B2 (en) * 2018-06-26 2025-04-29 Frank Hallock Ebetino Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof
WO2025019691A1 (en) * 2023-07-19 2025-01-23 Zymeron Corporation Drug conjugates for bone marrow protection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015560A1 (en) 1996-10-09 1998-04-16 Elizanor Biopharmaceuticals, Inc. Diphosphonate therapeutic compounds
JP2008536911A (ja) 2005-04-21 2008-09-11 ターガンタ セラピュティクス，インコーポレイティド ホスホン酸処理フルオロキノロン、その抗菌類似体および骨および関節感染の予防および治療方法
JP2009505974A (ja) 2005-08-11 2009-02-12 ターガンタ セラピュティクス，インコーポレイティド ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015560A1 (en) 1996-10-09 1998-04-16 Elizanor Biopharmaceuticals, Inc. Diphosphonate therapeutic compounds
JP2008536911A (ja) 2005-04-21 2008-09-11 ターガンタ セラピュティクス，インコーポレイティド ホスホン酸処理フルオロキノロン、その抗菌類似体および骨および関節感染の予防および治療方法
JP2009505974A (ja) 2005-08-11 2009-02-12 ターガンタ セラピュティクス，インコーポレイティド ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry，2008年10月，Vol. 16, No. 20，pp. 9217-9229，DOI: 10.1016/j.bmc.2008.09.010
Journal of Medicinal Chemistry，2017年02月13日，Vol. 60，No. 6，pp. 2326-2343
Journal of Medicinal Chemistry，2018年10月04日，Vol. 51，No. 21，pp. 6955-6969，DOI: 10.1021/jm801007z
新実験化学講座１５，丸善株式会社，1976年，1074頁
野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，pp.98-99

Also Published As

Publication number Publication date
WO2020014269A9 (en) 2020-03-05
WO2020014269A1 (en) 2020-01-16
JP2021532087A (ja) 2021-11-25
EP3820565A1 (en) 2021-05-19
EP3820565A4 (en) 2022-04-06
CN112672787A (zh) 2021-04-16
CA3105829A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US20240182504A1 (en) Bisphosphonate quinolone conjugates and uses thereof
Sedghizadeh et al. Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms
JP2023181185A (ja) ビスホスホネート・キノロン複合体及びそれらの用途
DE69428827T2 (de) Verwendung von Bisphosphorsäurederivaten zur Herstellung eines Medikamentes zur Förderung der Knochenheilung
Kün-Darbois et al. Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat
JP7501960B2 (ja) ビスホスホネート・キノロン複合体及びそれらの用途
KR102466337B1 (ko) 임플란트 주위염의 치료 방법
JP2011518169A (ja) 骨増殖を変化させるための化合物及び方法
Yaseen et al. Effects of local rosuvastatin/hyaluronan hydrogel on post-orthodontic relapse reduction in rabbits: histological and immunohistochemical study
CA3028343C (en) Bisphosphonate quinolone conjugates and uses thereof
Huang Investigating the role of bisphosphonates on bone cells and the potential of ionic therapy to restore bone regeneration in osteonecrosis of the jaw
US12285489B2 (en) Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof
Al-Shamaa et al. Remineralizing capacity of zinc oxide eugenol sealer following the addition of nanohydroxyapatite-tyrosine amino acid: An in vivo animal study
JP2022046536A (ja) ビスホスホネートの骨格除去
Abdallah Evaluation of a novel anabolic bone drug with synthetic bone graft biomaterials in a rat jaw bone defect
Prashanth et al. CLINICAL AND RADIOGRAPHIC COMPARISON OF EFFICACY OF 1.2% SIMVASTATIN AND 1% ALENDRONATE GEL AS A LOCAL DRUG DELIVERY SYSTEM IN THE TREATMENT OF CHRONIC PERIODONTITIS: A SPLIT MOUTH STUDY
Kato Biological Profile of Fast-Setting Calcium Silicate-Based Cements: In Vitro and Ex Vivo Evaluation
Azpur et al. Cyanoacrylate Tissue Adhesive as a Membrane in Socket Preservation: In Vitro Cytotoxicity and Clinical Evaluation
Ismail Development of novel remineralising antimicrobial brushite cements
Willett Bone Loss Quantification Following Extraction in Rats: A Foundation for Grafting and Regenerative Studies
Huang et al. The Effects of Regenerative Materials on Biomarkers, Clinical and Radiological Features of Healing Defects Treated by Guided Bone Regeneration
Siraj Evaluation and Comparison of Alendronate Gel with or Without Bioactive Glass, in the Treatment of Intrabony Defects”----A Clinico Radiographic Study
Cheng Effects of Timing of Bisphosphonate Treatment on Cleft Bone Grafting in an Animal Model
Veena Evaluation of an aminobisphosphonate (alendronate) as local drug delivery system in the management of periodontal osseous defects-a clinical and radiological study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240603

R150 Certificate of patent or registration of utility model

Ref document number: 7501960

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150